Introduction {#sec1}
============

In humans, the *O*-6-methylguanine-DNA methyltransferase (MGMT) protein, encoded by the *MGMT* gene located on chromosome 10 (10q26) \[[@B1]\], is involved in the DNA repair process \[[@B2],[@B3]\]. By means of methyl transfer, MGMT removes alkylating agents from the DNA direct reversal repair pathway and thus repairs the DNA \[[@B2],[@B3]\]. Two potential functional polymorphisms have been identified in the *MGMT* gene, namely rs12917 (Leu84Phe) and rs2308321 (Ile143Val) \[[@B4],[@B5]\]. In addition, the promoter methylation status of the gene is reportedly correlated with several clinical diseases, such as glioblastoma \[[@B6],[@B7]\], gastric cancer \[[@B8]\], and oral carcinoma \[[@B9]\].

Both genetic and environmental factors contribute to the occurrence and progression of clinical cancers \[[@B10],[@B11]\]. A number of studies have been conducted on the potential genetic effect of *MGMT* rs12917 polymorphism on its susceptibility to cancer, but the results were inconclusive. Before 2013, only three relative meta-analyses investigated the potential role of this polymorphism in the overall risk for cancer \[[@B12]\]. Based on the currently available data, we performed an updated meta-analysis to reassess the genetic relationship between *MGMT* rs12917 polymorphism and cancer risk. We enrolled a total of 54 case--control studies for the study.

Materials and methods {#sec2}
=====================

Database searching strategy {#sec2-1}
---------------------------

To identify potential publications, we searched four online electronic databases (PubMed, Embase, Cochrane Library, and WANFANG) up through August 2018. We used the terms 'MeSH (Medical Subject Headings)' and 'Entry Terms' to search PubMed and Cochrane Library, and 'Emtree' and 'Synonyms' for Embase. The search string we used for PubMed was as follows: (((((((((((((((O(6)-Methylguanine-DNA Methyltransferase \[MeSH Terms\]) OR Methylated-DNA-Protein-Cysteine S-Methyltransferase) OR Methylated DNA Protein Cysteine S Methyltransferase) OR S-Methyltransferase, Methylated-DNA-Protein- Cysteine) OR O(6)-Methylguanine Methyltransferase) OR O(6)-Alkylguanine-DNA Alkyltransferase) OR O(6)-MeG-DNA Methyltransferase) OR O(6)-Methylguanine DNA Transmethylase) OR Guanine-O(6)-Alkyltransferase) OR O(6)-AGT) OR DNA Repair Methyltransferase II) OR DNA Repair Methyltransferase I) OR MGMT)) AND ((((((((Polymorphism, Genetic \[MeSH Terms\]) OR Polymorphisms, Genetic) OR Genetic Polymorphisms) OR Genetic Polymorphism) OR Polymorphism (Genetics)) OR Polymorphisms (Genetics)) OR Polymorphism) OR Polymorphisms)) AND ((((((((((((((((((Neoplasms \[MeSH Terms\]) OR Neoplasia) OR Neoplasias) OR Neoplasm) OR Tumors) OR Tumor) OR Cancer) OR Cancers) OR Malignant Neoplasms) OR Malignant Neoplasm) OR Neoplasm, Malignant) OR Neoplasms, Malignant) OR Malignancy) OR Malignancies) OR Benign Neoplasms) OR Neoplasms, Benign) OR Benign Neoplasm) OR Neoplasm, Benign).

Article screening strategy {#sec2-2}
--------------------------

We designed our inclusion and exclusion criteria according to Patient, Intervention, Comparison and Outcome and Study design (PICOS) principles. We ruled out duplicates and screened improper articles. Exclusion criteria were as follows: (P), non-cancer patients; (I), other variants, gene expression or methylation; (C), lack of study controls or *P*-value of Hardy--Weinberg equilibrium (HWE) \<0.05; (O), lack of full genotype frequency data; (S), review, meta, poster, or meeting abstract. Eligible articles had to be designed as case--control studies, targetting the genetic relationship between *MGMT* rs12917 and cancer risk and containing the full genotype (C/C, C/T, T/T) frequencies in both cancer cases and negative controls.

Data extraction and quality assessment {#sec2-3}
--------------------------------------

After extracting usable data, we listed the basic information in tables. We assessed methodological quality via the Newcastle--Ottawa Scale (NOS) \[[@B15]\]. High-quality articles with NOS score \> 5 were regarded as eligible and included in our statistical analysis.

Statistical analysis {#sec2-4}
--------------------

We used STATA software version 12.0-SE (StataCorp, College Station, TX) to perform our analyses. We first assessed the inter-study heterogeneity using Cochran's Q statistic and the I^2^ test. A *P*-value of Cochran's Q statistic \< 0.1 or *I^2^* value \> 50% was considered to show a high level of heterogeneity. We thus used the DerSimonian--Laird association test with a random-effects model. Otherwise, we used the Mantel--Haenszel association test with a fixed-effects model. The *P*-value of association test, summary odds ratio (OR), along with the corresponding 95% confidence interval (CI) could be obtained for the allele (T compared with C), homozygous (T/T compared with C/C), recessive (T/T compared with C/C+C/T), heterozygous (C/T compared with C/C), dominant (C/T+T/T compared with C/C), and carrier (T compared with C) models.

We performed subgroup analyses by race, cancer type, and control source. Additionally, we assessed possible publication bias by means of Begg's and Egger's tests and evaluated the robustness of the results through sensitivity analysis.

Results {#sec3}
=======

Eligible case--control studies {#sec3-1}
------------------------------

[Figure 1](#F1){ref-type="fig"} depicts the flowchart for the identification of eligible case--control studies. We initially obtained a total of 537 articles by searching four databases, including PubMed (245 articles), Cochrane Library (1 article), Embase (241 articles), and WANFANG (50 articles). We then excluded 233 duplicates plus another 258 articles based strictly on our screening strategy. Finally, we identified 46 full-text articles for inclusion \[[@B4],[@B5],[@B16]\]. After data extraction and quality evaluation, we enrolled a total of 54 case--control studies free of poor quality (all NOS score \> 5) in our pooling analyses. The basic information and genotype frequency distribution are presented in Supplementary Table S1 and [Table 1](#T1){ref-type="table"}, respectively.

![Flowchart for the identification of eligible case--control studies](bsr-38-bsr20180942-g1){#F1}

###### Genotype and allele frequency of *MGMT* rs12917 in the enrolled case--control studies

  Authors                               Year          Genotype (case)   Allele (case)   Cancer type (case)   Genotype (control)          Allele (control)   HWE (control)                                                        
  ------------------------------------- ------------- ----------------- --------------- -------------------- --------------------------- ------------------ --------------------------- ------- ----- ----- ------ ------ ------ ------
  **Agalliu et al.** \[[@B16]\]         **2010**      949               269             32                   2167                        333                Prostate cancer^**1**^      916     298   23    2130   344    0.05   0.83
  106                                   35            6                 247             47                   Prostate cancer^**2**^      60                 20                          1       140   22    0.22   0.64          
  **Akbari et al.** \[[@B17]\]          **2009**      142               53              1                    337                         55                 Esophageal cancer           185     63    2     433    67     1.84   0.17
  **Betti et al.** \[[@B18]\]           **2011**      95                36              2                    226                         40                 MPM^**3**^                  179     64    8     422    80     0.59   0.44
  50                                    17            1                 117             19                   MPM^**4**^                  32                 12                          0       76    12    1.10   0.29          
  **Bye et al.** \[[@B19]\]             **2011**      225               111             10                   561                         131                Esophageal cancer^**1**^    300     155   14    755    183    1.28   0.26
  120                                   65            11                305             87                   Esophageal cancer^**5**^    294                116                         13      704   142   1.28   0.26          
  **Chae et al.** \[[@B20]\]            **2006**      344               84              4                    772                         92                 Lung cancer                 341     81    10    763    101    3.65   0.06
  **Chuang et al.** \[[@B21]\]          **2011**      1105              307             43                   2517                        393                Head and neck cancer        2256    823   81    5335   985    0.33   0.57
  **Doecke et al.** \[[@B22]\]          **2008**      416               136             14                   968                         164                Esophageal cancer           1029    281   27    2339   335    2.25   0.13
  **Felini et al.** \[[@B23]\]          **2007**      289               84              6                    662                         96                 Glioma                      369     84    6     822    96     0.24   0.63
  **Feng et al.** \[[@B24]\]            **2008**      96                58              47                   250                         152                Esophageal cancer           87      85    29    259    143    1.20   0.27
  **Gu et al.** \[[@B25]\]              **2009**      152               60              2                    364                         64                 Melanoma                    168     43    1     379    45     1.01   0.31
  **Hall et al.** \[[@B26]\]            **2007**      548               193             38                   1289                        269                UADT                        730     281   23    1741   327    0.44   0.51
  **Han et al.** \[[@B27]\]             **2006^1^**   344               82              8                    770                         98                 Endometrial cancer          822     242   21    1886   284    0.42   0.52
  **Han et al.** \[[@B28]\]             **2006^2^**   964               279             33                   2207                        345                Breast cancer               1,306   382   26    2994   434    0.10   0.75
  **Hu et al.** \[[@B29]\]              **2013**      389               130             24                   908                         178                Glioma                      405     84    6     894    96     0.48   0.49
  **Hu et al.** \[[@B4]\]               **2007**      418               77              5                    913                         87                 Lung cancer                 421     93    3     935    99     0.78   0.38
  **Huang et al.** \[[@B30]\]           **2017**      76                12              2                    164                         16                 Glioma                      75      14    1     164    16     0.14   0.71
  **Huang et al.** \[[@B31]\]           **2007**      372               156             11                   900                         178                Cervical cancer             592     198   10    1382   218    2.12   0.15
  **Huang et al.** \[[@B32]\]           **2010**      151               25              0                    327                         25                 Oral cancer                 89      21    0     199    21     1.22   0.27
  **Huang et al.** \[[@B33]\]           **2005^1^**   190               82              8                    462                         98                 Gastric cancer              279     99    9     657    117    0.00   0.95
  **Huang et al.** \[[@B34]\]           **2005^2^**   386               117             11                   889                         139                Head and neck cancer        529     204   21    1262   246    0.06   0.80
  **Inoue et al.** \[[@B35]\]           **2003**      55                18              0                    128                         18                 Primary brain cancer        160     55    9     375    73     2.24   0.13
  **Kiczmer** \[[@B36]\]                **2018**      49                11              9                    109                         29                 Head and neck cancer        168     66    5     402    76     0.25   0.61
  **Kietthubthew et al.** \[[@B37]\]    **2006**      84                21              1                    189                         23                 Oral cancer                 130     33    1     293    35     0.50   0.48
  **Li et al.** \[[@B38]\]              **2005**      132               34              1                    298                         36                 Bladder cancer              173     28    3     374    34     2.11   0.15
  **Liu et al.** \[[@B39]\]             **2002^1^**   53                7               0                    113                         7                  Lung cancer                 89      11    0     189    11     0.34   0.56
  **Liu et al.** \[[@B40]\]             **2002^2^**   21                3               0                    45                          3                  Gynecologic tumor           89      11    0     189    11     0.34   0.56
  26                                    8             0                 60              8                    Digestive system cancer     89                 11                          0       189   11    0.34   0.56          
  **Liu et al.** \[[@B41]\]             **2006**      82                16              2                    180                         20                 Esophageal cancer           57      8     0     122    8      0.28   0.60
  **Liu et al.** \[[@B42]\]             **2009**      299               62              8                    660                         78                 Glioma                      267     89    7     623    103    0.02   0.89
  **Loh et al.** \[[@B43]\]             **2011**      146               37              5                    329                         47                 Cancer                      894     212   14    2000   240    0.13   0.72
  **Lu et al.** \[[@B44]\]              **2006**      142               45              4                    329                         53                 Gastric cancer              186     59    6     431    71     0.26   0.61
  **McKean-Cowdin et al.** \[[@B45]\]   **2009**      774               204             20                   1752                        244                Glioblastoma                1,480   453   35    3413   523    0.00   0.96
  **O'Mara et al.** \[[@B46]\]          **2011**      889               261             23                   2039                        307                Endometrial cancer^**6**^   810     270   19    1890   308    0.42   0.52
  278                                   108           11                664             130                  Endometrial cancer^**7**^   296                103                         7       695   117   0.33   0.57          
  **Palli et al.** \[[@B47]\]           **2010**      210               77              4                    497                         85                 Gastric cancer              395     131   11    921    153    0.00   0.97
  **Rajaraman et al.** \[[@B48]\]       **2010**      265               77              9                    607                         95                 Glioma                      348     117   12    813    141    0.33   0.57
  102                                   23            4                 227             31                   Meningioma                  348                117                         12      813   141   0.33   0.57          
  52                                    12            2                 116             16                   Acoustic neuroma            348                117                         12      813   141   0.33   0.57          
  **Ritchey et al.** \[[@B49]\]         **2005**      123               36              2                    282                         40                 Prostate cancer             213     32    1     458    34     0.03   0.86
  **Shah et al.** \[[@B50]\]            **2012**      64                26              2                    154                         30                 Esophageal cancer           57      20    0     134    20     1.72   0.19
  **Shen et al.** \[[@B51]\]            **2005**      778               265             21                   1821                        307                Breast cancer               824     263   20    1911   303    0.03   0.85
  **Shen et al.** \[[@B52]\]            **2007**      432               112             11                   976                         134                NHL                         373     110   12    856    134    1.27   0.26
  **Shi et al.** \[[@B53]\]             **2011**      253               47              3                    553                         53                 AML                         459     91    4     1009   99     0.05   0.83
  **Stern et al.** \[[@B54]\]           **2007**      251               40              1                    542                         42                 Colorectal cancer           959     194   13    2112   220    0.81   0.37
  **Tranah et al.** \[[@B55]\]          **2006**      147               33              6                    327                         45                 Colorectal cancer^**8**^    1,634   471   32    3739   535    0.09   0.77
  204                                   47            6                 455             59                   Colorectal cancer^**9**^    330                93                          6       753   105   0.04   0.85          
  **Wang et al.** \[[@B5]\]             **2006**      832               259             30                   1923                        319                Lung cancer                 872     272   19    2016   310    0.18   0.67
  **Yang et al.** \[[@B56]\]            **2009**      33                14              1                    80                          16                 NHL                         289     58    5     636    68     1.10   0.29
  **Zhang et al.** \[[@B57]\]           **2008**      352               53              1                    757                         55                 Biliary track cancer        631     144   7     1406   158    0.15   0.70
  **Zhang et al.** \[[@B58]\]           **2010**      563               151             7                    1277                        165                Head and neck cancer        933     284   17    2150   318    0.78   0.38
  **Zienolddiny et al.** \[[@B59]\]     **2006**      189               102             13                   480                         128                Lung cancer                 247     106   10    600    126    0.12   0.73

Abbreviations: AML, acute myeloid leukemia; MPM, malignant mesothelioma; NHL, non-Hodgkin's lymphoma; UADT, upper aerodigestive tract.

**^1^**Data from Caucasian population. **^2^**Data from African population. **^3^**With population-based control. **^4^**With hospital-based control. **^5^**Data from mixed population. **^6^**Data from Australia. **^7^**Data from Poland. **^8^**With controls from Nurses' Health Study (NHS). **^9^**With controls from Physicians' Health Study (PHS) cohorts

Meta-analysis data {#sec3-2}
------------------

First, we studied the association between the *MGMT* rs12917 polymorphism and cancer risk via an overall meta-analysis. As shown in [Table 2](#T2){ref-type="table"}, we included a total of 54 case--control studies with 21010 cases and 34018 controls under the genetic models of allele T compared with C, C/T compared with C/C, C/T+T/T compared with C/C, and carrier T compared with C; meanwhile, we included 50 studies with 20716 cases and 33608 controls under the models of T/T compared with C/C and T/T compared with C/C+C/T. For the homozygous, recessive and carrier genetic models, we performed a Mantel--Haenszel association test with a fixed-effects model, and we observed no high degree of heterogeneity ([Table 2](#T2){ref-type="table"}; all *P*-values of heterogeneity \> 0.1; *I^2^* \< 50%). For other models (all *P*-values of heterogeneity \<0.001), we performed a DerSimonian--Laird association test with a random-effects model. Pooling data ([Table 2](#T2){ref-type="table"}) indicated an increased risk of cancer in cases compared with controls for the T/T compared with C/C (*P*-value of association test \<0.001; OR = 1.29) and T/T compared with C/C+C/T (*P*\<0.001; OR = 1.32) genetic models. Nevertheless, we failed to detect any statistical difference between cancer cases and negative controls under other genetic models ([Table 2](#T2){ref-type="table"}; all *P*\>0.05). Forest plot data are shown in [Figure 2](#F2){ref-type="fig"} and Supplementary Figures S1--S5; they revealed that the T/T genotype of the *MGMT* rs12917 polymorphism was likely to be associated with an increased susceptibility to cancer.

![Forest plot of meta-analysis (T/T compared with C/C model)](bsr-38-bsr20180942-g2){#F2}

###### Meta-analysis of the association between *MGMT* rs12917 and cancer susceptibility

  Models                          Sample size   Heterogeneity   Association                                        
  ------------------------------- ------------- --------------- ------------- ------- --------- -------- --------- -------------------
  **Allele T compared with C**    54            21010           34018         50.1%   \<0.001   Random   0.354     \-
  **T/T compared with C/C**       50            20716           33608         4.5%    0.384     Fixed    \<0.001   1.29 (1.14--1.46)
  **T/T compared with C/C+C/T**   50            20716           33608         3.2%    0.410     Fixed    \<0.001   1.32 (1.17--1.49)
  **C/T compared with C/C**       54            21010           34018         46.1%   \<0.001   Random   0.442     \-
  **C/T+T/T compared with C/C**   54            21010           34018         47.7%   \<0.001   Random   0.976     \-
  **Carrier T compared with C**   54            21010           34018         20.0%   0.104     Fixed    0.642     \-

-, OR (95% CI) data were not provided, when *P*-value of association \>0.05.

Subgroup analysis data {#sec3-3}
----------------------

Next, we carried out four subgroup analyses by race, cancer type, and control source. For the T/T compared with C/C model ([Table 3](#T3){ref-type="table"}), the association test data showed an increased cancer risk in the subgroups 'Caucasian' (*P*\<0.001; OR = 1.35), 'glioma' (*P*=0.022; OR = 1.70), 'population-based control (PB)' (*P*\<0.001; OR = 1.32) and 'hospital-based control (HB)' (*P*\<0.030; OR = 1.39). [Figure 3](#F3){ref-type="fig"} and Supplementary Figures S6--S7 present the forest plot data.

![Forest plot of subgroup analysis by race (T/T compared with C/C model)](bsr-38-bsr20180942-g3){#F3}

###### Data of subgroup analysis under T/T compared with C/C model

  Factor           Subgroup                Sample size   Heterogeneity   Association                             
  ---------------- ----------------------- ------------- --------------- ------------- ------- ------- --------- -------------------
  Race             Caucasian               27            13158           20678         0.0%    0.573   \<0.001   1.35 (1.15, 1.58)
                   African                 3             796             1104          0.0%    0.538   0.560     \-
                   Asian                   16            4031            6152          28.6%   0.136   0.088     \-
  Cancer type      Urinary system cancer   4             1725            1768          0.0%    0.526   0.174     \-
                   Esophageal cancer       8             2131            3907          0.0%    0.781   0.069     \-
                   Lung cancer             4             2357            2475          40.7%   0.167   0.155     \-
                   Head and neck cancer    14            5863            10581         39.5%   0.064   0.138     \-
                   Gastric cancer          3             762             1175          0.0%    0.692   0.891     \-
                   Blood cancer            3             906             1401          0.0%    0.702   0.882     \-
                   Colorectal cancer       3             735             3732          38.5%   0.197   0.416     \-
                   Brain cancer            9             2998            5030          17.4%   0.288   0.106     \-
                   Glioma                  5             1735            1884          37.9%   0.168   0.022     1.70 (1.08, 2.68)
  Control source   PB                      39            16526           26488         6.3%    0.358   \<0.001   1.32 (1.14, 1.52)
                   HB                      8             2482            4148          3.2%    0.405   0.030     1.39 (1.03, 1.86)

-, OR (95% CI) data were not provided, when *P-*value of association \> 0.05.

For the T/T compared with C/C+C/T model ([Table 4](#T4){ref-type="table"}), we also observed positive correlations in the subgroups 'Caucasian' (*P*\<0.001; OR = 1.37), 'Asian' (*P*=0.036; OR = 1.37), 'glioma' (*P*=0.026; OR = 1.68), 'PB' (*P*\<0.001; OR = 1.32), and 'HB' (*P*=0.004; OR = 1.52). Supplementary Figures S8--S10 present the forest plot data.

###### Data of subgroup analysis under T/T compared with C/C+C/T model

  Factor           Subgroup                Sample size   Heterogeneity   Association                             
  ---------------- ----------------------- ------------- --------------- ------------- ------- ------- --------- -------------------
  Race             Caucasian               27            13158           20678         0.0%    0.528   \<0.001   1.37 (1.17, 1.60)
                   African                 3             796             1104          0.0%    0.542   0.535     \-
                   Asian                   16            4031            6152          27.2%   0.150   0.036     1.37 (1.02, 1.83)
  Cancer type      Urinary system cancer   4             1725            1768          0.0%    0.527   0.152     \-
                   Esophageal cancer       8             2131            3907          0.0%    0.725   0.021     \-
                   Lung cancer             4             2357            2475          40.0%   0.467   0.174     \-
                   Head and neck cancer    14            5863            10581         37.5%   0.077   0.064     \-
                   Gastric cancer          3             762             1175          0.0%    0.718   0.815     \-
                   Blood cancer            3             906             1401          0.0%    0.769   0.901     \-
                   Colorectal cancer       3             735             3732          39.6%   0.191   0.344     \-
                   Brain cancer            9             2998            5030          3.0%    0.410   0.088     \-
                   Glioma                  5             1735            1884          23.7%   0.263   0.026     1.68 (1.07, 2.65)
  Control source   PB                      39            16526           26488         2.5%    0.426   \<0.001   1.32 (1.15, 1.52)
                   HB                      8             2482            4148          11.0%   0.344   0.004     1.52 (1.14, 2.03)

-, OR (95% CI) data was not provided, when *P*-value of association \> 0.05.

We did not detect positive results for the other genetic models (Supplementary Tables S2--S5; *P*\<0.05) except for the subgroups 'colorectal cancer' (Supplementary Table S3; *P*=0.041; OR = 0.79), 'HB' (Supplementary Table S3; *P*=0.027; OR = 0.86) under the C/T compared with C/C model; and the subgroup 'head and neck cancer' (Supplementary Table S5; *P*=0.020; OR = 0.92) under the carrier T compared with C model. Thus, the T/T genotype of *MGMT* rs12917 may have been associated with an increased risk of cancer in cases, especially the glioma cases, in the Caucasian population.

Publication bias and sensitivity analysis {#sec3-4}
-----------------------------------------

Begg's and Egger's tests indicated that results were free of possible publication bias (Supplementary Table S6; *P*\>0.05 for Begg's test, \>0.05 for Egger's test). A Begg's funnel plot with pseudo--95% confidence limits under the T/T compared with C/C model is shown in [Figure 4](#F4){ref-type="fig"}. In addition, we observed the same stable results in our subsequent sensitivity analysis; data from this analysis under the homozygous model ([Figure 5](#F5){ref-type="fig"}) are presented as an example.

![Begg's funnel plot with pseudo-95% confidence limits (T/T compared with C/C model)](bsr-38-bsr20180942-g4){#F4}

![Sensitivity analysis result (T/T compared with C/C model)](bsr-38-bsr20180942-g5){#F5}

Discussion {#sec4}
==========

We observed conflicting conclusions about the genetic role of *MGMT* rs12917 polymorphism in its susceptibility to different cancers. For instance, the polymorphism seems to be associated with the risk of esophageal cancer in the Chinese population \[[@B41]\], but not in the Kashmiri population \[[@B50]\]. This merits a quantitative synthesis via the meta-analytic approach. Although there were already three meta-analyses of the *MGMT* rs12917 polymorphism and its role in the overall risk for cancer \[[@B12]\], expanding the sample size and employing a distinct analysis strategy led to better results in our updated pooling analysis.

We did our best to gather candidate articles from four online databases. After screening them based on strict inclusion and exclusion criteria, we enrolled only the case--control studies that were of high quality and those that followed HWE. We ultimately included a total of 46 articles in our updated meta-analysis. After data extraction, we enrolled 54 case--control studies with 21010 cases and 34018 controls in the meta-analysis. We used the carrier, allele, homozygous, recessive, heterozygous, and dominant genetic models, and also confirmed the stability of the statistical results via sensitivity analysis.

In 2010, Zhong et al. \[[@B12]\] performed the first meta-analysis on this topic, reviewing 28 case--control studies from 26 articles \[[@B4],[@B5],[@B20],[@B22],[@B23],[@B26],[@B31],[@B33],[@B37],[@B38],[@B42],[@B45],[@B49],[@B51],[@B52],[@B54],[@B55],[@B59]\]. Another 24 case--control studies \[[@B16],[@B21],[@B24],[@B25],[@B29],[@B30],[@B32],[@B36],[@B39],[@B43],[@B44],[@B46],[@B50],[@B53],[@B56]\] were included in our study. We excluded three studies not in-line with the HWE principle \[[@B61]\] and one that focussed only on colorectal adenomatous or hyperplastic polyps but not on colorectal cancer \[[@B60]\]. In 2013, Du et al. \[[@B14]\] enrolled 41 case--control studies with 16643 cancer cases and 26720 negative controls from 37 articles \[[@B5],[@B16],[@B22],[@B26],[@B31],[@B37],[@B43],[@B44],[@B46],[@B47],[@B49],[@B64]\] in a meta-analysis. We excluded one of these studies \[[@B64]\] from our meta-analysis because it did not meet the requirement of full genotype frequency in both case and control groups. Finally, we enrolled another ten case--control studies \[[@B4],[@B21],[@B25],[@B29],[@B30],[@B35],[@B36],[@B42],[@B45],[@B48]\]. In addition, when compared with another meta-analysis of Liu et al. (2013) \[[@B13]\], which consisted of 44 case--control studies from 37 articles \[[@B4],[@B5],[@B16],[@B17],[@B19],[@B20],[@B22],[@B23],[@B25],[@B31],[@B35],[@B37],[@B38],[@B42],[@B43],[@B45],[@B49],[@B51],[@B52],[@B54],[@B65],[@B66]\], we excluded four studies that were not in HWE \[[@B61],[@B66]\], one that did not analyze colorectal cancer \[[@B60]\], and one that included other genetic variants \[[@B65]\]. We also added another 15 new case--control studies \[[@B18],[@B21],[@B24],[@B28],[@B34],[@B36],[@B39],[@B44],[@B48],[@B50],[@B53]\] for the analysis.

Our updated pooling analysis data demonstrated that cases had an overall enhanced risk for cancer when compared with negative controls under the T/T compared with C/C and T/T compared with C/C+C/T genetic models, especially in the European-descended population, which is partly consistent with the data of previous analyses \[[@B12]\]. Moreover, we observed that the *MGMT* rs12917 polymorphism is likely to be associated with the susceptibility to glioma, which is partly in-line with the two studies on the association between DNA repair gene polymorphisms and glioma risk \[[@B67],[@B68]\]. Nevertheless, owing to the limitation of sample size, the previous three meta-analyses of the overall risk for cancer did not conduct subgroup analyses of 'glioma' \[[@B12]\].

Some of the limitations to our meta-analysis are as follows: Although the sample sizes enrolled were quite large (21010 cases and 34018 controls), genotype data were very limited in many subgroup analyses. For instance, we used only three case--control studies in our analyses of the subgroups for gastric \[[@B33],[@B44],[@B47]\], blood \[[@B52],[@B53],[@B56]\], and colorectal \[[@B54],[@B55]\] cancers. Even for the subgroup analysis of 'glioma', with positive correlations under the T/T compared with C/C and T/T compared with C/C+C/T models, only five case--control studies \[[@B23],[@B29],[@B30],[@B42],[@B48]\] were included.We did not investigate the genetic effects of the *MGMT* rs12917 polymorphism in combination with other variants, such as rs2308321 of *MGMT*, rs25487 of X-ray cross-complementing group 1 (*XRCC1*), and rs13181 of xeroderma pigmentosum complementation group D (*XPD*), in certain specific cancers.We extracted certain demographic information such as the mean age at diagnosis and the sex of subject, but not other confounding factors such as lifestyle and clinical features. Moreover, we did not perform the relevant stratified meta-analyses due to lack of sufficient usable data.We detected significant heterogeneity amongst studies under the allele T compared with C, C/T compared with C/C, C/T+T/T compared with C/C, and carrier T compared with C genetic models. Complicating factors such as race and cancer type may be sources of inter-study heterogeneity. For instance, we detected decreased levels of heterogeneity in the 'Caucasian' and 'esophageal cancer' subgroups. Although we observed a positive conclusion in the 'glioma' subgroup, we failed to detect reduced inter-study heterogeneity. Only five case--control studies \[[@B23],[@B29],[@B30],[@B42],[@B48]\] were enrolled.There may be other undetected or unpublished articles containing potential eligible case--controls in other geographical locations or languages; in other words, our study may suffer from selection bias.Last but most important, our meta-analysis found a positive conclusion between *MGMT* rs12917 and the risk of cancer in general for the T/T compared with C/C and T/T compared with C/C+C/T models. Considering the distinct etiopathogenesis or pathogenesis of different kinds of cancers, more studies of large-scale populations of different ethnicities are required for a more scientific elucidation of *MGMT* rs12917's functional role in each particular cancer type.

To sum up, our updated pooling analysis offered additional evidence that *MGMT* rs12917 polymorphism is likely to be associated with an enhanced susceptibility to cancer overall, especially glioma, in the Caucasian population.
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HB

:   hospital-based control

HWE

:   Hardy--Weinberg equilibrium

MeSH

:   Medical Subject Heading

*MGMT*

:   *O*-6-methylguanine-DNA methyltransferase

NOS

:   Newcastle--Ottawa scale

OR

:   odds ratio

PB

:   population-based control
